Table 1.
Characteristics | |
---|---|
Patients, n | 22 |
Male (%) | 16 (72.7) |
Female (%) | 6 (27.3) |
Diagnosis | |
DLBCL (%) | 15 (68.2) |
tFL (%) | 5 (22.7) |
PMBCL (%) | 2 (9.1) |
Reinfused product | |
Tisagenlecleucel (%) | 17 (77.3) |
Axicabtagene ciloleucel (%) | 5 (22.7) |
Prior treatment lines, median (range) | 4 (2–6) |
bone marrow infiltration, n (%) | 17 (77.3) |
LDH at LD, median (range) | 277 (198–1542) |
≤ ULN (213 U/l) (%) | 3 (13.6) |
> ULN (213 U/l) (%) | 19 (86.4) |
DLBCL diffuse large B-cell lymphoma, tFL transformed follicular lymphoma, PMBCL primary mediastinal B-cell lymphoma, LDH lactate dehydrogenase, LD lymphodepletion, ULN upper level of normal